XML 27 R11.htm IDEA: XBRL DOCUMENT v3.26.1
Segments
 6 Months Ended
Jun. 30, 2026
Segments  
Segments

4. Segments

​

The Company views its operations and manages its business in one operating segment, that of the development and commercialization of drugs and antibodies that target critical elements of the immune system. The Company’s Chief Operating Decision Maker (“CODM”) is made up of the Chief Executive Officer and Chief Financial Officer. The CODM assesses performance for the segment and decides how to allocate resources based on consolidated net loss that is reported on the consolidated statement of operations and comprehensive loss. The measure of segment assets is reported on the balance sheet as total consolidated assets. Managing and allocating resources on a consolidated basis enables the CODM to assess the overall level of resources available and how to best deploy these resources across functions and programs that are in line with the Company’s long-term company-wide strategic goals.

​

The following table presents reportable segment net loss, including significant expense categories, attributable to the Company’s reportable segment for the three and six months ended June 30, 2026 and 2025 (in thousands):

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Three Months Ended

​

Six Months Ended

​

​

​

June 30, 

​

June 30, 

​

​

  ​ ​ ​

2026

  ​ ​ ​

2025

​

2026

  ​ ​ ​

2025

  ​ ​ ​

Compensation and benefits, excluding stock-based compensation

​

$

3,147

 

$

2,144

​

$

6,174

​

$

4,383

​

Stock-based compensation

​

​

2,609

 

​

1,256

​

​

5,259

 

​

2,507

​

Drug manufacturing

​

​

2,441

 

​

1,850

​

​

2,872

 

​

3,680

​

Clinical trials

​

​

5,410

 

​

2,135

​

​

10,453

 

​

4,062

​

Outside general and administrative

​

​

906

 

​

848

​

​

2,150

 

​

1,794

​

Facilities and insurance

​

​

630

 

​

504

​

​

1,188

 

​

1,284

​

Other segment items (1)

​

​

4,154

 

​

1,523

​

​

6,078

 

​

2,472

​

Total segment expense

​

​

19,297

 

​

10,260

​

​

34,174

 

​

20,182

​

Non-operating income, net

​

​

(1,338)

 

​

(2,262)

​

​

(2,523)

 

​

(27,377)

​

Net loss

​

$

17,959

 

$

7,998

​

$

31,651

 

$

(7,195)

​

(1)Includes consulting, non-clinical research and laboratory supplies.